The company manufactures specialized plastic-based fabrics used in hygiene products like diapers and sanitary pads, as well as in agricultural covers and industrial packaging. It earns revenue by converting polypropylene granules into non-woven rolls for business customers globally.
The company operates in a commoditized segment of the non-woven market where Chinese machinery is standard, limiting technical barriers. While high ROCE suggests efficiency, the low net margins and lack of long-term contracts indicate a lack of durable pricing power or a significant cost moat.
Management has focused on aggressive capacity expansion and vertical integration into solar power to lower costs. They recently acquired a majority stake in a consumer-facing export entity to move down the value chain, though the long-term returns on this diversification remain unproven.
The company's aggressive capacity expansion, funded by debt and government subsidies, hit a wall as the non-woven market became globally oversupplied. The lack of proprietary technology meant competitors easily replicated their process using the same Chinese machinery, crushing the already thin 3.4% net margins. As receivables stretched further, the working capital cycle collapsed, and the unproven pivot into B2C exports failed to offset the loss of major industrial clients, leading to a permanent impairment of capital.
RichFakir rates Spunweb Nonwoven Ltd's business quality as decent — 56/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Spunweb Nonwoven Ltd is trading about 21% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Spunweb Nonwoven Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Spunweb Nonwoven Ltd's fair value is about ₹93 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →